Personalized vaccine for fusion-positive sarcoma patients
Part of Cancer clinical trials.
This trial tests a personalized vaccine made from your tumor's unique gene fusion. It's for people with certain sarcomas that have spread and are now in remission or stable after standard treatment. The vaccine aims to help your immune system keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of sarcoma that has a specific gene fusion (like rhabdomyosarcoma, Ewing sarcoma, or synovial sarcoma) that has spread to other parts of your body.
- Your tumor must have been genetically tested through a special program (like INFORM, MASTER, or HEROES-AYA) to find the exact fusion sequence.
- You must be in complete remission or have only a few remaining tumor spots that have been treated with surgery or radiation.
- You must have finished all intensive chemotherapy and maintenance therapy.
- Your heart, kidney, and liver function must be working well enough (no severe organ problems).
- You cannot have other serious medical conditions like uncontrolled infections, autoimmune diseases, or recent live vaccines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized mRNA vaccine for people with rhabdomyosarcoma that hasn't responded to other treatments. The vaccine is designed to help your immune system fight the cancer.
This trial tests a personalized radiation therapy that adjusts the dose based on your tumor. It aims to improve treatment for Ewing sarcoma while limiting side effects.
This trial tests a combination of immune cells targeting sarcoma tumors. It is for people with advanced or recurrent sarcoma who have not responded well to standard treatments.
This trial tests a new drug called PEEL-224 combined with two chemotherapy drugs (vincristine and temozolomide) for people ages 12 to 49 with sarcoma that has come back or hasn't responded to standard treatments. The goal is to see if this combination is safe and effective.
This study tests a personalized vaccine made from your tumor's unique mutations, combined with special immune cells grown from your blood, to treat advanced sarcoma (bone or soft tissue cancer) that did not respond to initial treatment. The goal is to help your immune system recognize and attack cancer cells.
This Phase 1 study tests a custom vaccine made to match a specific cancer genetic change (DNAJB1-PRKACA fusion). It’s combined with an approved immunotherapy (immune checkpoint inhibitor) to help your immune system recognize and fight the cancer. You may be considered if your cancer is advanced or has spread and you meet several blood/organ and health requirements.
Hear when a new Ewing Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.